The IGF-I response to very low rhGH doses is preserved in human ageing

• Published in: Clinical endocrinology (Oxford) Vol. 49; no. 6; pp. 757 - 763
• Main Authors: Arvat, Emanuela, Ceda, Gianpaolo, Ramunni, Josefina, Lanfranco, Fabio, Aimaretti, Gianluca, Gianotti, Laura, Broglio, Fabio, Ghigo, Ezio
• Format: Journal Article
• Language: English
• Published: Oxford BSL Blackwell Science Ltd 01-12-1998; Blackwell; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aging - metabolism; Analysis of Variance; Biological and medical sciences; Blood Glucose - analysis; Drug Administration Schedule; Estradiol - blood; Female; Hormones. Endocrine system; Human Growth Hormone - administration & dosage; Humans; Insulin - blood; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-Like Growth Factor I - metabolism; Male; Medical sciences; Pharmacology. Drug treatments; Statistics, Nonparametric; Testosterone - blood; Thyrotropin - blood; Thyroxine - blood; Triiodothyronine - blood; Italy; Europe; Human; Low dose; Treatment efficiency; Single dose; Somatotropin hormone; Insulin like growth factor 1; Blood plasma; Chemotherapy; Adenohypophyseal hormone; Young adult; Recombinant protein; Elderly; Age; Comparative study
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1046/j.1365-2265.1998.00613.x

OBJECTIVES
The activity of the GH/IGF‐I axis varies during life and is clearly reduced in the elderly. In fact, GH, IGF‐I and IGFBP‐3 levels in older people are clearly reduced and similar to those observed in patients with GH deficiency. The declining activity of the GH/IGF‐I axis with advancing age may contribute to changes in body composition, structure, function and metabolism. In fact, treatment with pharmacological doses of rhGH restored plasma IGF‐I levels, increased lean body mass and muscle strength while decreased adipose tissue mass in healthy elderly subjects. At present it is unclear whether peripheral GH sensitivity is preserved in aging. To clarify this point, we aimed to verify the effect of both single dose and short term treatment with very low rhGH doses on the IGF‐I levels in normal elderly subjects. Normal young adults were studied as controls.
DESIGN
We studied the IGF‐I response to rhGH administration after single (20 μg/kg s.c.) or repeated administrations (5 μg/kg s.c. for 4 days) in two groups of young and elderly subjects.
SUBJECTS
Twenty‐seven healthy elderly (ES, 14 F and 13 M, age mean ± SEM: 69.4 ± 1.3 years, BMI: 23.9 ± 0.5 kg/m2) and 21 young adult subjects (YS, 12 F and 9 M, 29.8 ± 1.2 years, 23.8 ± 0.5 kg/m2) were studied, divided into two groups.
MEASUREMENTS
Group 1: blood samples for IGF‐I and IGFBP‐3 assay were drawn basally and 12 h after rhGH administration (20 μg/kg). Group 2: blood samples for IGF‐I, IGFBP‐3, glucose and insulin assays were drawn basally, 12 h after the first and the last rhGH administration (5 μg/kg). Free T3 (fT3), free T4 (fT4) and TSH levels were also assayed basally and after the last rhGH administration; oestradiol and testosterone levels were measured basally.
RESULTS
Basal IGF‐I levels were lower in ES (whole group) than in YS (whole group) (123.1 ± 8.9 vs. 230.4 ± 16.1 μg/l, P < 0.001) while IGFBP‐3 levels in the two groups were similar (2.7 ± 0.2 vs. 3.1 ± 0.2 mg/l). No sex‐related differences in IGF‐I and IGFBP‐3 levels were recorded in either group. Group 1: the single administration of 20 μg/kg rhGH induced a significant (P < 0.001) IGF‐I rise both in YS (318.0 ±25.3 vs. 256.0 ± 21.6 μg/l) and ES (187.2 ± 16.8 vs. 100.4 ± 9.5 μg/l). IGF‐I levels after rhGH in ES persisted lower than those in YS (P < 0.001), but the percentage IGF‐I increase after rhGH was higher (P < 0.001) in ES (91.6 ± 12.9%) than in YS (23.9 ± 5.0%) subjects. Both in YS and ES IGFBP‐3 levels were significantly increased to the same extent by 20 μg/kg rhGH (3.0 ± 0.2 vs. 2.3 ±0.2 mg/l; 2.9 ±0.2 vs. 2.6 ± 0.2 mg/l, P < 0.001 vs. baseline). Group 2: basal glucose, insulin, fT3, fT4 and TSH levels in YS and ES were similar; testosterone levels in aged and young men were similar while oestradiol levels in aged women were lower (P < 0.01) than in the young ones. IGF‐I levels were significantly increased 12 h after the first administration of 5 μg/kg rhGH both in ES (166.6 ± 15.7 vs. 138.3 ± 12.1 μg/l, P < 0.03) and YS (272.2 ± 16.1 vs. 230.4 ± 16.1 μg/l, P < 0.001). Twelve hours after the last rhGH administration IGF‐I levels were further increased (P < 0.001) both in ES (208.7 ± 21.1 μg/l) and YS (301.7 ± 17.6 μg/l). IGF‐I levels in ES persisted lower than those in YS at each time point (P < 0.001); however, the percentage IGF‐I increase after rhGH in ES and YS was similar (after the first administration: 22.4 ± 5.1 vs. 21.7 ± 5.1%; after the last administration: 52.9 ± 9.5 vs. 39.5 ± 9.9%). No significant variation in IGFBP‐3, glucose, insulin, fT3, fT4 or TSH levels was recorded in either ES or YS.
CONCLUSIONS
Our data demonstrate that IGF‐I levels in aging are reduced but the peripheral sensitivity to rhGH is preserved. In fact, in aged subjects the percentage rhGH‐induced IGF‐I increase is similar or even higher than that in young controls. Our findings also indicate that a very low rhGH dose is needed in aged subjects to restore IGF‐I levels to the young range.